Sabine Tejpar
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 1%
- Pathology and Forensic Medicine top 0.5%
- Hepatology top 1%
- Molecular Biology top 10%
- Co-authors
- Eric Van CutsemFortunato CiardielloMichael SchlichtingIlhan CelikGunnar FolprechtDavid CunninghamClaus-Henning KöhneJoan Maurel
- Topics
- Colorectal Cancer Treatments and Studies (62 papers)Lung Cancer Treatments and Mutations (24 papers)Genetic factors in colorectal cancer (20 papers)
- Partner nations
- BelgiumUnited StatesItaly
In The Last Decade
Sabine Tejpar
77 papers receiving 5.2k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 4.1k
- Pulmonary and Respiratory Medicine 1.9k
- Pathology and Forensic Medicine 1.7k
- Hepatology 929
- Molecular Biology 927
Countries citing papers authored by Sabine Tejpar
This map shows the geographic impact of Sabine Tejpar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Tejpar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Tejpar more than expected).
Fields of papers citing papers by Sabine Tejpar
This network shows the impact of papers produced by Sabine Tejpar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Tejpar. The network helps show where Sabine Tejpar may publish in the future.
Co-authorship network of co-authors of Sabine Tejpar
This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Tejpar. A scholar is included among the top collaborators of Sabine Tejpar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Tejpar. Sabine Tejpar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 3 | |
| 3 | 2 | |
| 4 | 69 | |
| 5 | 94 | |
| 6 | Identification of a Poor-Prognosis BRAF-Mutant Like Populationof Patients With Colon Cancer. Journal of Clinical Oncology,30(12):12BB-1295, 2012 | 1 |
| 7 | 27 | |
| 8 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Statusbreakdown → | 1441 |
| 9 | Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab | 3 |
| 10 | 30 | |
| 11 | Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial | 2 |
| 12 | 52 | |
| 13 | 63 | |
| 14 | Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. | 9 |
| 15 | The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri | 11 |
| 16 | Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data | 5 |
| 17 | Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study | 1 |
| 18 | Standard treatment for metastatic colorectal cancer (CRC) | 3 |
| 19 | 29 | |
| 20 | 269 |
About Sabine Tejpar
Sabine Tejpar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 78 papers that have together received 5.3k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (62 papers), Lung Cancer Treatments and Mutations (24 papers) and Genetic factors in colorectal cancer (20 papers). The work is most often cited by research in Oncology (4.1k citations), Hepatology (929 citations) and Pathology and Forensic Medicine (1.7k citations). Sabine Tejpar has collaborated with scholars based in Belgium, United States and Italy. Frequent co-authors include Eric Van Cutsem, Fortunato Ciardiello, Michael Schlichting, Ilhan Celik, Gunnar Folprecht, David Cunningham, Claus-Henning Köhne, Joan Maurel, Stefano Cascinu and Philippe Rougier. Their work appears in journals such as The Lancet, JAMA and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.